Literature DB >> 30406218

The role of β-elimination for the clinical activity of hypomethylating agents and cyclophosphamide analogues.

Haritha Reddy1, Alison Duffy2, Noa G Holtzman1, Ashkan Emadi1.   

Abstract

A beta-elimination reaction generally involves the cleavage of a sigma (σ) bond at the position beta (β) to a pair of electrons that departs a molecule via a nucleophilic leaving group, subsequently leading to the formation of a new pi (π) bond. We describe the importance of β-elimination reactions in the mechanisms of action of two classes of chemotherapeutic agents. First, we evaluate the chemical steps resulting in formation of 5-methyl-cytosine and its disassociation from DNA methytransferase (DNMT) by β-elimination reaction. When carbon 5 (C5) of cytosine is substituted with a nitrogen atom (N) in 5-aza-cytosine analogues, the critical β-elimination reaction cannot proceed, which results in the permanent attachment of 5-aza-cytosine to DNMT. The net outcome is entrapment of the DNMT by 5-aza-cytosine analogues and its eventual degradation, leading to DNA hypomethylation. Second, we analyze the critical role of β-elimination reaction in the activation of cyclophosphamide and ifosfamide. The incapability of undergoing β-elimination results in reduction of the cytotoxic activity of these agents. It appears that the conversion of aldehyde group, in aldophosphamide metabolites of cyclophosphamide and ifosfamide, to carboxyl group by aldehyde dehydrogenase makes the protons on the carbon atom attached to carboxyl group not acidic enough that can be removed under physiologic conditions via initiation of the critical β-elimination reaction. This ultimately culminates in selective cytotoxic effect of these agents against lymphocytes but not hematopoietic and other stem cells with high aldehyde dehydrogenase content.

Entities:  

Year:  2016        PMID: 30406218      PMCID: PMC6217992     

Source DB:  PubMed          Journal:  Am J Cancer Ther Pharmacol


  13 in total

Review 1.  DNA methylation and gene silencing in cancer.

Authors:  Stephen B Baylin
Journal:  Nat Clin Pract Oncol       Date:  2005-12

2.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Authors:  William Blum; Ramiro Garzon; Rebecca B Klisovic; Sebastian Schwind; Alison Walker; Susan Geyer; Shujun Liu; Violaine Havelange; Heiko Becker; Larry Schaaf; Jon Mickle; Hollie Devine; Cheryl Kefauver; Steven M Devine; Kenneth K Chan; Nyla A Heerema; Clara D Bloomfield; Michael R Grever; John C Byrd; Miguel Villalona-Calero; Carlo M Croce; Guido Marcucci
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

Review 3.  DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers.

Authors:  Shinichi Fukushige; Akira Horii
Journal:  Tohoku J Exp Med       Date:  2013-03       Impact factor: 1.848

Review 4.  Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.

Authors:  Tae Kon Kim; Steven D Gore; Amer M Zeidan
Journal:  Semin Hematol       Date:  2015-04-08       Impact factor: 3.851

5.  Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Farhad Ravandi; Theresa Liu-Dumlao; Mark Brandt; Stefan Faderl; Sherry Pierce; Gautam Borthakur; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Blood       Date:  2012-10-15       Impact factor: 22.113

Review 6.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

Review 7.  Update on the pharmacotherapy for myelodysplastic syndromes.

Authors:  Vu H Duong; Rami S Komrokji; Alan F List
Journal:  Expert Opin Pharmacother       Date:  2014-07-31       Impact factor: 3.889

8.  Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).

Authors:  Bernard Tawfik; Sarunas Sliesoraitis; Susan Lyerly; Heidi D Klepin; Julia Lawrence; Scott Isom; Leslie R Ellis; Megan Manuel; Sarah Dralle; Dmitriy Berenzon; Bayard L Powell; Timothy Pardee
Journal:  Ann Hematol       Date:  2013-10-23       Impact factor: 3.673

9.  Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.

Authors:  Bhavana Bhatnagar; Vu H Duong; Theodore S Gourdin; Michael L Tidwell; Ching Chen; Yi Ning; Ashkan Emadi; Edward A Sausville; Maria R Baer
Journal:  Leuk Lymphoma       Date:  2014-02-04

Review 10.  Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.

Authors:  Tara M Robinson; Paul V O'Donnell; Ephraim J Fuchs; Leo Luznik
Journal:  Semin Hematol       Date:  2016-01-15       Impact factor: 3.851

View more
  2 in total

1.  Method Development and Validation for Measuring O6-Methylguanine in Dried Blood Spot Using Ultra High-Performance Liquid Chromatography Tandem Mass Spectrometry.

Authors:  Yahdiana Harahap; Aurelia Maria Vianney; Herman Suryadi
Journal:  Drug Des Devel Ther       Date:  2021-03-03       Impact factor: 4.162

2.  Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.

Authors:  Jorge Enrique Rojas-Rivera; Sol Carriazo; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2019-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.